20.73

0.72% -0.15

Oculis Holding Ag (OCS)

Overview News Price History Discussions Forecast

Oculis Holding Ag stock is traded at $20.73, with a volume of 91,801. It is down -0.72% in the last 24 hours and up +9.68% over the past month. Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Previous Close:

$20.88

Open:

$20.9

24h Volume:

91,801

Relative Volume:

1.05

Market Cap:

$1.20B

Revenue:

Net Income/Loss:

$-75.28M

P/E Ratio:

-10.39

EPS:

-1.9957

Net Cash Flow:

$-57.45M

1W Performance:

-4.38%

1M Performance:

+9.68%

6M Performance:

+5.34%

1Y Performance:

+24.99%

1-Day Range:

$20.54

$21.00

1-Week Range:

$20.10

$21.86

52-Week Range:

$14.00

$23.08

Oculis Holding Ag Stock (OCS) Company Profile

Name

Oculis Holding Ag

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

Address

Employee

Twitter

Next Earnings Date

Latest SEC Filings

OCS's Discussions on Twitter

Compare OCS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OCS Oculis Holding Ag	20.73	1.21B	0	-75.28M	-57.45M	-1.9957
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Oculis Holding Ag Stock (OCS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-27-25	Initiated	Needham	Buy
Dec-05-23	Initiated	Chardan Capital Markets	Buy
Oct-05-23	Initiated	Stifel	Buy
Jun-14-23	Initiated	BofA Securities	Buy
Jun-12-23	Initiated	H.C. Wainwright	Buy
Jun-08-23	Initiated	Robert W. Baird	Outperform
May-10-23	Initiated	Pareto	Buy
Apr-28-23	Initiated	Wedbush	Outperform

View All

Oculis Holding Ag Stock (OCS) Latest News

02:31 AM

Analyzing ABVC BioPharma (NASDAQ:ABVC) & Oculis (NASDAQ:OCS) - Defense World

02:31 AM

Dec 09, 2025

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - Yahoo Finance

Dec 09, 2025

Dec 08, 2025

Oculis (NASDAQ:OCS) Trading Down 6%Should You Sell? - MarketBeat

Dec 08, 2025

Wall Street Analysts Predict a 106.04% Upside in Oculis Holding AG (OCS): Here's What You Should Know - Zacks Investment Research

Dec 08, 2025

Dec 06, 2025

Oculis (NASDAQ:OCS) Trading 7% HigherHere's What Happened - MarketBeat

Dec 06, 2025

Oculis (Nasdaq: OCS) accelerates Privosegtor into registrational optic neuropathy trials - Stock Titan

Dec 06, 2025

Lifesci Capital Weighs in on Oculis FY2025 Earnings - Defense World

Dec 06, 2025

Dec 05, 2025

Lifesci Capital Forecasts Oculis FY2025 Earnings - MarketBeat

Dec 05, 2025

Will Oculis Holding AG stock benefit from commodity prices2025 Volume Leaders & Community Consensus Trade Signals - Newser

Dec 05, 2025

Dec 04, 2025

Is Oculis Holding’s New Equity Shelf Shaping a More Flexible Capital Strategy for OCS Investors? - simplywall.st

Dec 04, 2025

Oculis (NASDAQ:OCS) Coverage Initiated at Lifesci Capital - MarketBeat

Dec 04, 2025

How analysts revise price targets for Oculis Holding AG (CR5) stockMarket Movers & Low Drawdown Momentum Ideas - Newser

Dec 04, 2025

Why Oculis Holding AG (CR5) stock is upgraded to buyMarket Activity Report & Weekly Chart Analysis and Guides - Newser

Dec 04, 2025

How Oculis Holding AG Equity Warrant stock performs in interest rate cycles2025 Winners & Losers & Verified Swing Trading Watchlists - Newser

Dec 04, 2025

Dec 03, 2025

LifeSci Capital Initiates Coverage of Oculis Holding (OCS) with Outperform Recommendation - Nasdaq

Dec 03, 2025